64466-47-3 Usage
Uses
Used in Pharmaceutical Synthesis:
1-(4,7-Dimethoxy-2-benzofuranyl)ethanone is used as an intermediate in the synthesis of pharmaceuticals and organic compounds. Its unique chemical structure allows for the creation of a variety of drugs with different therapeutic applications.
Used in Drug Discovery and Development:
In the field of medicinal chemistry, 1-(4,7-Dimethoxy-2-benzofuranyl)ethanone is used as a compound of interest for drug discovery and development. Its potential biological activities, such as antipsychotic and anti-inflammatory effects, make it a promising candidate for the development of new therapeutic agents.
Used in Biological Research:
1-(4,7-Dimethoxy-2-benzofuranyl)ethanone is also utilized in biological research to study its various potential applications, including its antipsychotic and anti-inflammatory properties. This research can contribute to the understanding of the compound's mechanisms of action and its potential use in treating various medical conditions.
Used in the Chemical Industry:
As a chemical compound with a unique structure, 1-(4,7-Dimethoxy-2-benzofuranyl)ethanone can be used in the chemical industry for the development of new materials and products, taking advantage of its specific properties and reactivity.
Check Digit Verification of cas no
The CAS Registry Mumber 64466-47-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,4,4,6 and 6 respectively; the second part has 2 digits, 4 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 64466-47:
(7*6)+(6*4)+(5*4)+(4*6)+(3*6)+(2*4)+(1*7)=143
143 % 10 = 3
So 64466-47-3 is a valid CAS Registry Number.
InChI:InChI=1/C12H12O4/c1-7(13)8-6-16-12-10(15-3)5-4-9(14-2)11(8)12/h4-6H,1-3H3
64466-47-3Relevant academic research and scientific papers
Discovery of Potent Protease-Activated Receptor 4 Antagonists with in Vivo Antithrombotic Efficacy
Miller, Michael M.,Banville, Jacques,Friends, Todd J.,Gagnon, Mark,Hangeland, Jon J.,Lavallée, Jean-Fran?ois,Martel, Alain,O'Grady, Harold,Rémillard, Roger,Ruediger, Edward,Tremblay, Fran?ois,Posy, Shana L.,Allegretto, Nick J.,Guarino, Victor R.,Harden, David G.,Harper, Timothy W.,Hartl, Karen,Josephs, Jonathan,Malmstrom, Sarah,Watson, Carol,Yang, Yanou,Zhang, Ge,Wong, Pancras,Yang, Jing,Bouvier, Michel,Seiffert, Dietmar A.,Wexler, Ruth R.,Lawrence, R. Michael,Priestley, E. Scott,Marinier, Anne
, p. 7400 - 7416 (2019/08/26)
In an effort to identify novel antithrombotics, we have investigated protease-activated receptor 4 (PAR4) antagonism by developing and evaluating a tool compound, UDM-001651, in a monkey thrombosis model. Beginning with a high-throughput screening hit, we identified an imidazothiadiazole-based PAR4 antagonist chemotype. Detailed structure-activity relationship studies enabled optimization to a potent, selective, and orally bioavailable PAR4 antagonist, UDM-001651. UDM-001651 was evaluated in a monkey thrombosis model and shown to have robust antithrombotic efficacy and no prolongation of kidney bleeding time. This combination of excellent efficacy and safety margin strongly validates PAR4 antagonism as a promising antithrombotic mechanism.
